

NATIONAL INSTITUTE FOR HEALTH CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	Proposal:	Proposal made by:	Action taken: Removed/Added/Not included/Noted	Justification:
1.	Action Heart	NICE Secretariat	Removed	This organisation does not have a national focus to be included on the matrix of consultees and commentators. Action Heart has been removed from the matrix under 'Patient groups'.
2.	British Association for Services to the Elderly	NICE Secretariat	Removed	This organisation has ceased and no longer exists. British Association for Services to the Elderly has been removed for the matrix under 'Professional groups'

National Institute for Health and Clinical Excellence

Consultation comments on the provisional matrix for the technology appraisal of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Issue date: April 2014

Appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix

3.	Independent Age (formerly Counsel and Care)	NICE Secretariat	Removed	This organisation has requested to be removed from all matrices. Independent Age has been removed from the matrix under 'Patient Group'
4.	Cardiac Risk in the Young	NICE Secretariat	Included	This organisation has an area of interest closely related to this appraisal and meets the selection criteria to participate in this appraisal. Cardiac Risk in the Young has been added to the matrix of consultees and commentators under 'patient' groups.
5.	Coronary Prevention Group	NICE Secretariat	Included	This organisation has an area of interest closely related to this appraisal and meets the selection criteria to participate in this appraisal. Coronary Prevention Group has been added to the matrix of consultees and commentators under 'patient' groups.
6.	Pumping Marvellous	Pumping Marvellous	Included	This organisation has an area of interest closely related to this appraisal and meets the selection criteria to participate in this appraisal. Pumping Marvellous has been added to the matrix of consultees and commentators under 'patient' groups.

National Institute for Health and Clinical Excellence

Consultation comments on the provisional matrix for the technology appraisal of rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome

Issue date: April 2014

Appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix

7.	<p>We suggest that the following comparator manufacturers are removed:</p> <ul style="list-style-type: none"> • Actavis UK (clopidogrel) • Arrow Generics (clopidogrel) • Aspire Pharma (clopidogrel) • AstraZeneca (ticagrelor) • Daiichi Sankyo (prasugrel) • Dexcel Pharma (clopidogrel) • Dr Reddy's Laboratories (clopidogrel) • Lilly UK (prasugrel) • Mylan (clopidogrel) • Ratiopharm UK (clopidogrel) • Teva UK (clopidogrel) • Wockhardt UK (clopidogrel) 	NICE Secretariat	Removed	<p>Clopidogrel is not considered a comparator as rivaroxaban is an add-on to clopidogrel. Prasugrel and ticagrelor are antiplatelet agents used in dual antiplatelet therapy for some people with ACS. It is not anticipated that the marketing authorisation for rivaroxaban will cover rivaroxaban as an add-on to DAPT including prasugrel or DAPT including ticagrelor. During consultation, consultees were asked whether prasugrel or ticagrelor should be comparators for rivaroxaban, and the manufacturers of these drugs were included in the matrix in order for them to comment. Following consultation it was determined that a relevant comparator for rivaroxaban should be an add on treatment to dual antiplatelet therapy (DAPT) rather than alternative DAPT to clopidogrel with aspirin.</p>
----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------	---------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------